Elekta announced that the UK’s National Health Service (NHS) will acquire 10 Flexitron® afterl oading platforms used to treat a variety of the most common cancers with brachytherapy.
The systems have been ordered by the NHS Supply Chain and the order will be booked in the second quarter of Elekta’s fiscal year 2018-19.
Brachytherapy is a highly targeted form of radiotherapy where a radiation source is placed inside or next to the area that requires treatment. It is commonly used to treat cancers of the cervix, prostate, breast, and skin. When used as a boost in combination with external beam radiation therapy, brachytherapy historically has increased survival rates significantly.
Flexitron provides patients with the most sophisticated and safe brachytherapy procedure possible, while clinicians benefit from a simpler, more intuitive brachytherapy workflow.
Steve Tomkins, Elekta’s Business Unit Manager for UK, Ireland and Nordics, said: “We are very happy that the NHS is investing in this essential treatment modality – brachytherapy can offer unsurpassed accuracy and efficiency in treatment delivery. And through the NHS Supply Chain, this equipment can be utilized by both existing customers as well as clinics with competing systems as they are replaced.”
Steve added: “Elekta is the market leader for brachytherapy solutions both in the UK and globally, a position gained through our demonstrated commitment and innovation. In addition to Flexitron, Elekta also offers our new Venezia gynecological applicator for patients with advanced cervical cancer. Both these systems are supported by Elekta’s BrachyAcademy, an educational program to advance the successful use of brachytherapy.”
To learn more, visit elekta.com/flexitron.